▼Tocilizumab for rheumatoid arthritis
Abstract
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid arthritis.1 Unlike currently available biological agents, the drug targets the pro-inflammatory cytokine interleukin-6 (IL-6). Here, we consider the place of tocilizumab in rheumatoid arthritis and whether it offers any advantages over other biological agents.
Footnotes
-
↵* For an explanation on non-inferiority trials, please see DTB 2008; 46: 55–6.
